Integra LifeSciences Completes The Sale Of Its Extremity Orthopedics Business To Smith+Nephew

IndustryPRwire - Integra LifeSciences Holdings announced it has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew.

“With this divestiture, we will now be in an even stronger position to capitalize on our core products and technologies in neurosurgery and regenerative medicine, and provide greater value to our customers and shareholders,” said Peter Arduini, president and CEO, Integra LifeSciences. “We want to thank the orthopedics team for their contributions to Integra’s success and wish them all the best for their future.”

Piper Sandler & Co. is serving as financial advisor and Morgan, Lewis & Bockius LLP is acting as legal advisor to Integra.

About Integra LifeSciences

Integra LifeSciences is a global leader in regenerative technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Certas®, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, SurgiMend®, TCC-EZ®, and VersaTru®. For the latest news and information about Integra and its products, please visit

Related Posts

Subscribe Our Newsletter